Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy

1. To assess the incidence of IDH1 and IDH2 mutations in adult AML patients, and to explore their associations with the patients' clinical, cytogenetic, and molecular characteristics as well as with treatment response and outcome. 2. To delineate the similarities and distinctions among mutations at IDH1-R132, IDH2-R140 and IDH2-R172 in AML, both clinically and molecularly (including cytogenetics, immunophenotyping, mutation co-occurrence patterns). 3. The results can be references for future selection of targeted therapy (targeting IDH mutant proteins).

Sex

All

Minimum age

20 Years

Maximum age

100 Years

Inclusion criteria:

1. Patients ≥20 Years with Diagnosed Acute Myeloid Leukemia
2. Willing to provide voluntary written informed consent before study related procedures

Exclusion criteria:

1. Not acute myeloid leukemia patients
2. Patients \<20 Years with Diagnosed Acute Myeloid Leukemia